IBA SA: transparency notification
22 Mars 2019 - 6:30PM
IBA SA: transparency notification
IBA – TRANSPARENCY
NOTIFICATION
Louvain-la-Neuve, Belgium, March 22,
2019, 17.35 - IBA (Ion Beam Applications SA), the world’s
leading provider of proton therapy solutions for the treatment of
cancer, announces that it has to issue a transparency notification,
in accordance with Article 14, al. 1 of the Transparency Law of May
2, 2007 on disclosure of major holdings, further to the
notification received on March 21, 2019.
|
Reason for the notification |
Upwards crossing of the 3% threshold further to the acquisition of
shares –and thus voting rights- held as loan collateral |
|
Persons subject to the notification requirement |
IBA SA, émetteur |
|
Persons that dispose of voting rights |
Norges Bank |
|
Transaction date |
21/03/2019 |
|
Threshold that is crossed (in %) |
3% Upwards crossing further to the acquisition of voting
rights |
|
Dénominator |
30 122 528 |
|
|
Voting rights (number) |
923 989 |
|
|
Voting rights (%) |
3,07 |
% |
|
Chain of control |
Norges Bank is the central bank of Norway. As part of its central
bank activities, Norges Bank manages Norway’s foreign exchange
reserves and is responsible for management of the Norwegian
Government Pension Fund Global (GPFG). The formal responsibility
for management of the GPFG is placed with the Ministry of Finance,
but is delegated to Norges Bank. All investments are executed by
Norges Bank acting as principal and all holdings are registered in
the name of Norges Bank. |
About IBAIBA (Ion Beam
Applications S.A.) is a global medical technology company focused
on bringing integrated and innovative solutions for the diagnosis
and treatment of cancer. The company is the worldwide technology
leader in the field of proton therapy, considered to be the most
advanced form of radiation therapy available today. IBA’s proton
therapy solutions are flexible and adaptable, allowing customers to
choose from universal full-scale proton therapy centers as well as
compact, single room solutions. In addition, IBA also has a
radiation dosimetry business and develops particle accelerators for
the medical world and industry. Headquartered in Belgium and
employing about 1,500 people worldwide, IBA has installed systems
across the world.
IBA is listed on the pan-European stock exchange
NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB). More
information can be found at: www.iba-worldwide.com
For further information, please contact:
IBA
Stephanie BauwinLegal Counsel+32 10 203
924Stephanie.bauwin@iba-group.com
- 20190322transparencyNorgesEN
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024
